Natera’s Solomon Moshkevich on How MRD Testing Pinpoints Cancer Recurrence

Why It Matters

Signatera’s ability to pinpoint microscopic disease reshapes post‑surgery treatment decisions, potentially reducing overtreatment and improving patient outcomes, while opening new revenue streams for Natera.

Key Takeaways

• Signatera detects tumor DNA in blood, offering early recurrence insight
• FDA cleared Signatera CDx as companion diagnostic for bladder cancer immunotherapy
• Over 50% of oncologists ordered Signatera in the last quarter
• Medicare covers Signatera for colorectal, breast, bladder, ovarian, and lung cancers
• Natera targets multi‑cancer early detection, beginning with colorectal trial

Pulse Analysis

Molecular residual disease (MRD) testing has emerged as a game‑changer in oncology by interrogating circulating tumor DNA (ctDNA) rather than relying solely on imaging or tissue biopsies. Natera’s Signatera leverages a patient‑specific genetic fingerprint to quantify minute amounts of tumor DNA, enabling clinicians to track tumor dynamics in real time. This heightened sensitivity can reveal microscopic disease that would otherwise be invisible on a CT scan, allowing earlier intervention and more precise assessment of therapeutic response. As a result, oncologists are increasingly using serial MRD assays to personalize adjuvant treatment strategies.

The recent FDA clearance of Signatera CDx as a companion diagnostic for Genentech’s atezolizumab in muscle‑invasive bladder cancer underscores the test’s clinical credibility. In the pivotal trial, patients who remained ctDNA‑negative for a year achieved a 100 % one‑year survival rate, demonstrating that treatment can be safely deferred until molecular recurrence is detected. This evidence challenges the traditional “treat‑all‑post‑surgery” model and promises to reduce overtreatment, toxicities, and costs. Coupled with Medicare coverage for several solid‑tumor indications, the regulatory win accelerates payer adoption and revenue growth for Natera.

Looking beyond the current portfolio, Natera is channeling resources into multi‑cancer early detection, with colorectal cancer slated as the first FDA submission. If successful, a blood‑based screen could complement existing colonoscopy programs and capture high‑risk individuals before lesions become radiographically apparent. The market for pan‑cancer liquid biopsies is projected to exceed $10 billion within the next decade, but widespread uptake hinges on robust clinical validation and reimbursement pathways. Natera’s strategy of building evidence‑driven indications while expanding insurance coverage positions it to capture a sizable share of this emerging segment.